Delving into the Latest Updates on Ornidazole with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Orinidazole, Ornidazole (USAN/INN)

+ [7]

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

AmebiasisAnaerobic bacterial infectionGiardiasis+ [1]

Inactive Indication

Dysentery, AmebicLiver Abscess, AmebicUrogenital infection by Trichomonas vaginalis

Originator Organization

Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.

Active Organization

Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 2001),

AmebiasisAnaerobic bacterial infectionGiardiasis+ [1]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC7H10ClN3O3

InChIKeyIPWKIXLWTCNBKN-UHFFFAOYSA-N

CAS Registry16773-42-5

The proliferation of hazardous substances in natural environments, driven by industrial advancements, poses significant threats to ecosystems.Traditional anal. methods struggle with the detection of these pollutants due to their diversity and often trace concentrationsThis work introduces two novel metal-organic frameworks (MOFs) synthesized from 2,6-bis(1-imidazolyl) naphthalene and transition metal ions for the first time.The MOFs were comprehensively characterized via using single-crystal X-ray diffraction (SCXRD), powder X-ray diffraction (PXRD), elemental anal. (EA), IR (IR) spectroscopy and thermogravimetric anal. (TGA), further confirming their high purity, thermal stability and water resistance.Furthermore, the MOFs′ fluorescence sensing was thoroughly tested, indicating high sensitivity and selectivity of Fe³⁺, CrO^2-₄, Cr₂O^2-₇, acetone and nitroimidazole antibiotics.In addition, MOF 1 shows higher sensitive for DMZ than that of MOF 2.The outstanding stability and sensing of as-prepared samples via energy transfer or competitive absorption highlight their promise for environmental and medical sensing as well as advancing chem. sensor technol.

01 Apr 2025·Journal of Hazardous Materials

Sunlight-mediated environmental risks of tinidazole in seawater: A neglected ocular toxicity of photolysis mixtures

Article

Author: Feng, Mingbao ; He, Shanshan ; Zheng, Ruping ; Shen, Yingjia ; Li, Qiuru ; Li, Xinyue ; He, Jinlin ; Chen, Shengyue ; Zhang, Shengqi ; Zha, Wenqi

Tinidazole (TNZ), a common nitroimidazole antibiotic, is pervasive in aquatic ecosystems, posing potential threats to marine organisms. The environmental fate of TNZ, particularly under solar irradiation, and the associated secondary risks are not well characterized. Herein, the photochemical reactivity of TNZ and four other typical nitroimidazoles (i.e., metronidazole, ornidazole, dimetridazole, and secnidazole) were quantified for multiple photoreactive species. The photolysis products of these nitroimidazoles were identified under solar irradiation, from which the reaction pathways were tentatively proposed. Furthermore, the photo-induced toxicity evolution mechanisms of TNZ were investigated by comparing phenotypic, transcriptomic, and metabolomic changes in marine medaka embryos (Oryzias melastigma) after exposure to TNZ and its photo-irradiated mixtures. Our results indicated that the photo-irradiated TNZ enhanced visual toxicity to marine medaka embryos compared to the parent compound. The photolysis mixtures induced embryonic ocular malformation and significantly affected the expression of the associated genes with the initiation/termination of the phototransduction cascade, leading to metabolite changes related to visual impairment. This work reported the first comprehensive assessment of the photolysis-mediated environmental fate and secondary risks of TNZ in seawater. The findings highlighted the necessity of including complex photolysis mixtures under solar irradiation in future chemical risk assessments of marine environments.

01 Mar 2025·Journal of Hazardous Materials

β-cyclodextrin polymers as a new sorbent for solid-phase extraction of xenobiotics in Urine

Article

Author: Liao, Yicheng ; Sun, Peizhe ; Luo, Junhuai ; Fu, Xiaoli ; Meng, Yuan ; Liu, Minqi

This study systematically assessed the performance of a newly developed solid-phase extraction (SPE) material, cellulose-supported aminated β-cyclodextrin polymer (amine-β-CDP@Cellulose), in determining 44 xenobiotics, encompassing endocrine-disrupting chemicals (EDCs), pharmaceuticals, and food additives in urine samples. The primary objective of the research was to synthesize a new sorbent, optimize the extraction protocol, and elucidate the underlying adsorption and desorption mechanisms. Following optimization, it was observed that amine-β-CDP@Cellulose achieved recoveries ranging from 80 % to 120 % for 28 of the 44 targeted xenobiotics, with only three compounds showing recoveries below 50 %. The superior extraction performance of this novel material can be attributed to the synergistic effects of its structural components: charged functional groups introduced via the cross-linking agent, the hydrophobic cyclodextrin cavity that facilitates inclusion complexation, and abundant hydroxyl groups that enhance adsorption. Additionally, the study included a comparative analysis between amine-β-CDP@Cellulose and commercially available HLB resins. This comparative analysis revealed that the amine-β-CDP@Cellulose method effectively mitigated matrix interferences while maintaining comparable extraction efficiency to the HLB-based method. Collectively, these findings suggest that amine-β-CDP@Cellulose could serve as a sustainable and cost-effective material for extracting xenobiotics from complex matrices.

100 Deals associated with Ornidazole

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D05274	Ornidazole	P01AB03 J01XD03 G01AF06	DB13026

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Amebiasis	China	Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.	01 Jan 2001
Anaerobic bacterial infection	China	Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.	01 Jan 2001
Giardiasis	China	Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.	01 Jan 2001
Trichomonas Infections	China	Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.	01 Jan 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anaerobic bacterial infection	Discovery	China	-	10 Oct 2013
Dysentery, Amebic	Discovery	China	-	10 Oct 2013
Giardiasis	Discovery	China	-	10 Oct 2013
Liver Abscess, Amebic	Discovery	China	-	10 Oct 2013
Urogenital infection by Trichomonas vaginalis	Discovery	China	-	10 Oct 2013